# Efficacy and Safety of Empagliflozin in NODAT

> **NCT03642184** · PHASE4 · TERMINATED · sponsor: **RenJi Hospital** · enrollment: 6 (actual)

## Conditions studied

- New Onset Diabetes After Transplant
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT03642184
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-14
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Difficult in enrolling suitable participants
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642184, "Efficacy and Safety of Empagliflozin in NODAT". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03642184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*